Page 86 - 《中国药房》2024年24期

Ther，2022，44（12）：1604-1623. 2022，42（1）：7-13.
[ 4 ] PATTERSON T F，THOMPSON G R 3rd，DENNING D [14] U.S. Department of Health and Human Services，National
W，et al. Practice guidelines for the diagnosis and manage‐ Institutes of Health，National Cancer Institute. Common
ment of aspergillosis：2016 update by the Infectious Diseases Terminology Criteria for Adverse Events（CTCAE）ver‐
Society of America[J]. Clin Infect Dis，2016，63（4）：e1-e60. sion 5.0[EB/OL].（2017-11-27）[2024-08-08].https：//www.
[ 5 ] HAMADA Y，TOKIMATSU I，MIKAMO H，et al. Prac‐ doc88.com/p-8495997221823.html.
tice guidelines for therapeutic drug monitoring of voricona- [15] BÉNICHOU C. Criteria of drug-induced liver disorders.
zole：a consensus review of the Japanese Society of Che‐ Report of an international consensus meeting[J]. J Hepa‐
motherapy and the Japanese Society of Therapeutic Drug tol，1990，11（2）：272-276.
Monitoring[J]. J Infect Chemother，2013，19（3）：381-392. [16] GARCIA-CORTES M，ROBLES-DIAZ M，STEPHENS
[ 6 ] ASHBEE H R，BARNES R A，JOHNSON E M，et al. C，et al. Drug induced liver injury：an update[J]. Arch
Therapeutic drug monitoring（TDM）of antifungal agents： Toxicol，2020，94（10）：3381-3407.
guidelines from the British Society for Medical Mycology [17] TAGHVAYE-MASOUMI H， HADJIBABAIE M，
[J]. J Antimicrob Chemother，2014，69（5）：1162-1176. GHADIMI M，et al. Association of voriconazole trough
[ 7 ] ZHOU L J，LI M，LI H H，et al. Establishment of a mathe- plasma concentration with efficacy and incidence of hepa‐
matical prediction model for voriconazole stable mainte‐ totoxicity in Iranian patients with hematological malignan‐
nance dose：a prospective study[J]. Front Cell Infect Mi‐ cies[J]. Iran J Pharm Res，2021，20（1）：62-71.
crobiol，2023，13：1157944. [18] SUZUKI Y，TOKIMATSU I，SATO Y，et al. Association
[ 8 ] WANG T T，MIAO L Y，SHAO H，et al. Voriconazole of sustained high plasma trough concentration of voricona-
therapeutic drug monitoring and hepatotoxicity in criti‐ zole with the incidence of hepatotoxicity[J]. Clin Chim
cally ill patients：a nationwide multi-centre retrospective Acta，2013，424：119-122.
study[J]. Int J Antimicrob Agents，2022，60（5/6）：106692. [19] JIN H Y，WANG T S，FALCIONE B A，et al. Trough con‐
[ 9 ] ZHOU P Y，LIM T P，TANG S L S，et al. The utility of centration of voriconazole and its relationship with effi‐
voriconazole therapeutic drug monitoring in a multi-racial cacy and safety：a systematic review and meta-analysis[J].
cohort in Southeast Asia[J]. J Glob Antimicrob Resist， J Antimicrob Chemother，2016，71（7）：1772-1785.
2020，21：427-433. [20] WANG Y，WANG T T，XIE J，et al. Risk factors for
[10] SHEN K L，GU Y，WANG Y，et al. Therapeutic drug voriconazole-associated hepatotoxicity in patients in the
monitoring and safety evaluation of voriconazole in the intensive care unit[J]. Pharmacotherapy，2016，36（7）：
treatment of pulmonary fungal diseases[J]. Ther Adv Drug 757-765.
Saf，2022，13：20420986221127503. [21] 林良沫，洪绵慧，吴丹娜，等. 血药浓度监测与伏立康唑
[11] 中华医学会重症医学分会. 重症患者侵袭性真菌感染诊 致肝损伤的发生情况及影响因素分析[J]. 中国感染与化
断与治疗指南：2007[J]. 中华内科杂志，2007，46（11）： 疗杂志，2023，23（6）：709-714.
960-966. LIN L M，HONG M H，WU D N，et al. Incidence and risk
Chinese Society of Critical Care Medicine.Guidelines for factors of voriconazole-induced liver injury in the context
diagnosis and treatment of invasive fungal infection in of therapeutic drug monitoring[J]. Chin J Infect Che‐
severe patients：2007[J]. Chin J Intern Med，2007，46 mother，2023，23（6）：709-714.
（11）：960-966. [22] LIN L M，FU X J，HONG M H. Lower prealbumin and
[12] 中国医药生物技术协会药物性肝损伤防治技术专业委 higher CRP increase the risk of voriconazole overexpo‐
员会，中华医学会肝病学分会药物性肝病学组 . 中国药 sure and adverse reactions[J]. Cureus，2023，15（9）：
物性肝损伤诊治指南：2023 年版[J]. 中华肝脏病杂志， e46107.
2023，31（4）：355-384. [23] SHAH R R，SMITH R L. Inflammation-induced pheno‐
Technology Committee on DILI Prevention and Manage‐ conversion of polymorphic drug metabolizing enzymes：
ment，Chinese Medical Biotechnology Association，Study hypothesis with implications for personalized medicine[J].
Group of Drug-induced Liver Disease，Chinese Medical Drug Metab Dispos，2015，43（3）：400-410.
Association for the Study of Liver Disease.Chinese guide‐ [24] HIRATA A，NOTO K，OTA R，et al. Voriconazole trough
line for diagnosis and management of drug-induced liver concentration and hepatotoxicity in patients with low
injury：2023 version[J]. Chin J Hepatol，2023，31（4）： serum albumin [J]. Int J Clin Pharmacol Ther，2019，57
355-384. （3）：135-143.
[13] 高飞，周丽娟，李敏，等. 高效液相色谱法监测侵袭性真 [25] LEVIN M D，DEN HOLLANDER J G，VAN DER HOLT
菌感染患者伏立康唑血药浓度及临床应用分析[J]. 中国 B，et al. Hepatotoxicity of oral and intravenous voricona-
医院药学杂志，2022，42（1）：7-13. zole in relation to cytochrome P450 polymorphisms[J]. J
GAO F，ZHOU L J，LI M，et al. Determination of voricona- Antimicrob Chemother，2007，60（5）：1104-1107.
zole in serum of patients with invasive fungal infection by （收稿日期：2024-07-17 修回日期：2024-12-03）
HPLC and its clinical application[J]. Chin J Hosp Pharm， （编辑：陈 宏）

· 3040 · China Pharmacy 2024 Vol. 35 No. 24 中国药房 2024年第35卷第24期